Hiroyuki NAKAHIRA et al. Atty. Dkt.: Q93343 Preliminary Amendment

Page 2

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

(original): A compound represented by the formula (I):

wherein R¹ is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group;

the solid line and dotted line between A^1 and A^2 indicate a double bond ($A^1=A^2$) or a single bond ($A^1=A^2$);

 A^1 is a nitrogen atom or a group represented by the formula $C(R^2)$ and A^2 is a group represented by the formula $C(R^4)$, in the case of the solid line and dotted line between A^1 and A^2 being a double bond $(A^1=A^2)$;

 A^1 is a group represented by the formula $C(R^2)(R^3)$ and A^2 is a group represented by the formula $C(R^4)(R^5)$, in the case of the solid line and dotted line between A^1 and A^2 being a single bond (A^1-A^2) ;

 R^1 and R^2 may be taken together with the adjacent nitrogen atom and carbon atom to form an optionally substituted 4- to 7-membered ring in the case of the solid line and dotted line between A^1 and A^2 being a double bond ($A^1 = A^2$) and A^1 being a group represented by the

Hiroyuki NAKAHIRA et al. Atty. Dkt.: Q93343 Preliminary Amendment Page 3

formula C(R2);

R² is a hydrogen atom, a halogen atom, a cyano group, a formyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkyloxy group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted amino group, an optionally substituted carbamovl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, an optionally substituted aryl group, an optionally substituted aryloxy group, an optionally substituted aryloxycarbonyl group, an optionally substituted aralkyl group, an optionally substituted aralkyloxy group, an optionally substituted aroyl group, an optionally substituted arylthio group, an optionally substituted arylsulfinyl group, an optionally substituted arylsulfonyl group, an optionally substituted alkylthio group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylalkyl group, an optionally substituted heteroarylcarbonyl group, an optionally substituted heteroaryloxy group, an optionally substituted alkylcarbonyl group, an optionally substituted cycloalkylcarbonyl group, or an optionally substituted nitrogen-containing saturated heterocyclic group;

R³ is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted aryl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxy group, an optionally

Hiroyuki NAKAHIRA et al. Atty. Dkt.: Q93343 Preliminary Amendment

Page 4

arylsulfonyl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylalkyl group, an optionally substituted heteroarylcarbonyl group, an optionally substituted heteroarylcarbonyl group, or an optionally substituted alkylcarbonyl group;

R⁴ and R⁵ are independently a hydrogen atom, a halogen atom, a cyano group, an optionally substituted alkyl group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxycarbonyl group, an optionally substituted aryloxy group, an optionally substituted heteroaryl group, an optionally substituted heteroarylalkyl group, an optionally substituted

R⁶ is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted vinyl group, an optionally substituted ethynyl group, an optionally substituted nitrogen-containing saturated heterocyclic group, or an optionally substituted heteroaryl group; and

-Y is any of groups represented by the formula (A), formula (B), formula (C) and formula (D) shown below:

$$NH_2$$
 (A)

Preliminary Amendment

Page 5

wherein m1 is 0, 1, 2 or 3, and R^7 is absent or one or two R^7 s are present and are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted alkyl group, an optionally substituted arralkyl group, an optionally substituted arralkyl group, an optionally substituted amino group, a carboxyl group, an optionally substituted alkoxycarbonyl group or an optionally substituted carbamoyl group, or two R^7 s, when taken together, represent methylene or ethylene and may bind to one or more carbon atoms constituting the ring, to form a new ring;

wherein m2 is 0, 1, 2 or 3, and R^8 is absent or one or two R^8 s are present and are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted alkoxy group, an optionally substituted aralkyl group, an optionally substituted aralkyl group, an optionally substituted amino group, a carboxyl group, an optionally substituted alkoxycarbonyl group or an optionally substituted carbamoyl group, or two R^8 s, when taken together, represent methylene or ethylene and may bind to one or more carbon atoms constituting the ring, to form a new ring;

wherein m3 and m4 are independently 0 or 1, and R9 is absent or one or two R9s are present and

Preliminary Amendment

Page 6

are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted aralkyl group, an optionally substituted alkoxycarbonyl group or an optionally substituted carbamoyl group, or two R⁹s, when taken together, represent methylene or ethylene and may bind to one or more carbon atoms constituting the ring, to form a new ring; and

wherein m5 is 1, 2 or 3, R¹⁰ is absent or one or two R¹⁰s are present and are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted aralkyl group, an optionally substituted arralkyl group, an optionally substituted arranged group, or two R¹⁰s, when taken together, represent methylene or ethylene and may bind to one or more carbon atoms constituting the ring, to form a new ring, and R¹¹ and R¹² are independently a hydrogen atom, methyl, ethyl, propyl or isopropyl, or R¹¹ and R¹², when taken together with the adjacent carbon atom, represent cyclopropyl, cyclobutyl or cyclopentyl,

- a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.
- (original): A compound according to claim 1, which is represented by the formula (II):

Hiroyuki NAKAHIRA et al. Atty. Dkt.: Q93343 Preliminary Amendment Page 7

wherein A³ is a nitrogen atom or a group represented by the formula C(R²), and R¹, R², R⁴, R⁶ and Y are as defined in claim 1, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug.

(original): A compound, a prodrug thereof or a pharmaceutically acceptable salt
of the compound or prodrug according to either of claims 1 and 2, wherein R⁶ is the following
formula (E), formula (F) formula (F):

wherein Z is an oxygen atom, the formula S(O)p or N(R¹⁹);

R¹³ is absent or one or two R¹³s are present and are independently a halogen atom, a hydroxyl group, a formyl group, a carboxyl group, a cyano group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, an optionally substituted amino group, an optionally substituted carbamoyl group, an alkoxycarbonyl group, an optionally substituted alkylcarbonyl group, a cycloalkylcarbonyl group, an optionally substituted phenyl group, an optionally

Hiroyuki NAKAHIRA et al.

Atty. Dkt.: Q93343 Preliminary Amendment

Page 8

substituted heteroaryl group or a nitrogen-containing saturated heterocyclic group, or two R¹³s, when taken together, represent a C₁₋₃ alkylenedioxy group:

R¹⁴ is absent or one or two R¹⁴s are present and are independently a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group or a haloalkoxy group;

R¹⁵ is methyl, ethyl, a chlorine atom or a bromine atom;

R¹⁶ is a hydrogen atom, methyl, ethyl, a chlorine atom or a bromine atom:

R17 is a hydrogen atom, methyl or ethyl;

R18 is a hydrogen atom, methyl, ethyl, cyclopropyl or cyclobutyl;

p is 0, 1 or 2; and

R19 is a hydrogen atom or an alkyl group.

- (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt
 of the compound or prodrug according to claim 3, wherein R⁶ is the formula (E) or the formula
 (H).
- 5. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 4, wherein R⁶ is the formula (E) and one or two R¹³ are present and are independently a halogen atom, a cyano group, an alkylthio group, an alkylsulfonyl group, a C₁₃ alkylenedioxy group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group or a haloalkoxy group.
- (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt
 of the compound or prodrug according to either of claims 1 and 2, wherein R⁶ is the following
 formula (I):

Hiroyuki NAKAHIRA et al. Atty. Dkt.: Q93343 Preliminary Amendment Page 9

wherein R^{20} is a halogen atom, a cyano group, an alkylthio group, an alkylsulfonyl group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group or a haloalkoxy group, and R^{21} is a hydrogen atom or a fluorine atom.

- (currently amended): A compound, a prodrug thereof or a pharmaceutically
 acceptable salt of the compound or prodrug according to any one of elaims 1 to 6claim 1,
 wherein Y is the formula (A) or (B).
- (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of elaims 1 to 6claim 1, wherein Y is the formula (A).
- 9. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 8claim 1, wherein R² is a hydrogen atom, a cyano group, an optionally substituted alkeyl group, an optionally substituted alkeyl group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, an optionally substituted aryl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted aroll group, an optionally substituted heteroaryl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylcarbonyl group or an optionally substituted alkylcarbonyl group.

Preliminary Amendment

Page 10

- 10. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 8claim 1, wherein R² is a hydrogen atom, a cyano group, an optionally substituted alkyl group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, an optionally substituted aryl group, an optionally substituted alkylcarbonyl group.
- 11. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 10claim 1, wherein R⁴ is a hydrogen atom, an optionally substituted alkyl group, a cyano group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted aryl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted heteroaryl group, an optionally substituted heteroaryl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylcarbonyl group or an optionally substituted alkylcarbonyl group.
- 12. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 10 claim 1, wherein R⁴ is a hydrogen atom or an optionally substituted alkyl group.
- (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 10claim 1,

Hiroyuki NAKAHIRA et al.

Atty. Dkt.: Q93343 Preliminary Amendment

Page 11

wherein R^4 is the formula: $-C(R^{22})(R^{23})-A^4-R^{24}$ in which R^{22} and R^{23} are independently a hydrogen atom, methyl, ethyl, propyl, isopropyl, methoxy or ethoxy, or R^{22} and R^{23} , when taken together with the adjacent carbon atom, represent cyclopropyl, cyclobutyl or cyclopentyl; A^4 is a single bond, methylene or ethylene; and R^{24} is a hydrogen atom, a cyano group, an alkyl group, a haloalkyl group, a cycloalkyl group, a tetrahydrofuranyl group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted aryloxy group, an optionally substituted aryloxy group, an optionally substituted aryloxycarbonyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted alkylcarbonyl group, an optionally substituted alkylcarbonyl group.

- 14. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 13claim 1, wherein R¹ is a hydrogen atom, an optionally substituted alkyl group of 1 to 3 carbon atoms, or an optionally substituted aryl group, and the substituten(s) of the optionally substituted alkyl group is selected from fluorine atom, optionally substituted aryl groups, carboxyl group, optionally substituted alkoxycarbonyl groups, optionally substituted aryl groups and optionally substituted aryloxy groups.
- 15. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 13 claim 1, wherein R¹ is a hydrogen atom, methyl or a group represented by the formula: -Ra-Rb-Rc in which

Ra is an alkylene chain;

Rb is a single bond or a carbonyl group; and

Preliminary Amendment

Page 12

Re is an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted aryl group, an optionally substituted heteroaryloxy group or an optionally substituted aryloxy group.

- 16. (currently amended): A pharmaceutical composition comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 15 claim 1 as an active ingredient.
- 17. (currently amended): A dipeptidyl peptidase IV inhibitor comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 15 claim 1 as an active ingredient.
- 18. (currently amended): A pharmaceutical composition for the treatment of diabetes comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 15 claim 1 as an active ingredient.
- 19. (currently amended): Use of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 45claim 1 in the manufacture of a dipeptidyl peptidase IV inhibitor.
- 20. (currently amended): Use of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 15claim 1 in the manufacture of a pharmaceutical composition for the treatment of diabetes.
- 21. (currently amended): A method for treating diabetes comprising administering an effective amount of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 1 to 15claim 1 to a patient who needs treatment